Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,992 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MYOPATHY Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

NCT04033926
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
KZR-616, Placebo
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Orange, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS

NCT04026425
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Interventions
Two-day cardiopulmonary exercise test
Other
Lead sponsor
Ithaca College
Other
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Ithaca, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 31, 2026, 1:18 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mirror Neurons in Older Participants

NCT03946709
View directory record Official record
Conditions
Muscle Weakness, Dynapenia, Sarcopenia
Interventions
Action Observation
Other
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

NCT02657993
View directory record Official record
Conditions
Breast Neoplasms, Musculoskeletal Pain
Interventions
Hypnosis, Attention Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 31, 2026, 1:18 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional

OMT vs. Standard Therapy in the Management of Acute Neck and Low Back Pain in the Emergency Department

NCT06987578
View directory record Official record
Conditions
Acute Pain
Interventions
OMT vs. Ibruprofen
Other
Lead sponsor
St. Joseph's Regional Medical Center, New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 31, 2026, 1:18 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

NCT07642635
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Semaglutide (Rybelsus®), Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tailored Self-Management of Temporomandibular Disorders (TMD) Using Health Information Technology

NCT03036215
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction Syndrome
Interventions
PACT Experimental Arm
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 31, 2026, 1:18 AM EDT
Completed No phase listed Observational

Effects of Soft Tissue Lengthening on Gait in Children With Spasticity

NCT04090892
View directory record Official record
Conditions
Muscle Spasticity
Interventions
selective percutaneous muscle release
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
4 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional

Using a Patient Navigator to Address the Social Drivers of Health in the Management of Pain

NCT06665906
View directory record Official record
Conditions
Pain
Interventions
Web-Based Cognitive Behavioral Therapy (PainTrainer), Social Intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

NCT01674634
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
XIAFLEX / XIAPEX
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional

Physiological Changes Induced Through MEP Conditioning in People With SCI

NCT04286191
View directory record Official record
Conditions
Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions
Operant Conditioning, Control Group
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 31, 2026, 1:18 AM EDT
Recruiting No phase listed Observational

Post-contracture Release Radiation for Dupuytren's Disease

NCT04122313
View directory record Official record
Conditions
Dupuytren's Disease, Dupuytren Contracture, Dupuytren Disease of Palm and Finger, Dupuytren Disease of Finger, Dupuytrens Contracture of Both Hands, Dupuytren's Disease of Palm of Right Hand, Dupuytren's Disease of Palm of Left Hand, Dupuytren Contracture of Right Palm, Dupuytren Contracture of Left Palm, Dupuytren's Contracture Left, Dupuytren's Contracture Right
Interventions
Evaluation of Dupuytren's Disease Treatment
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional Results available

A Community Wellness Program for Adults Living With Long-term Physical Disability

NCT03653390
View directory record Official record
Conditions
Physical Disability
Interventions
EnhanceWellness for Disability (EW-D), Wellness Education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 64 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 31, 2026, 1:18 AM EDT
Recruiting No phase listed Observational

Systemic Biomarkers of Brain Injury From Hyperammonemia

NCT04602325
View directory record Official record
Conditions
Urea Cycle Disorder, Organic Acidemia, Maple Syrup Urine Disease, Glutaric Acidemia I, Fatty Acid Oxidation Disorder, Hypoxic-Ischemic Encephalopathy
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Not applicable Interventional

Treatment of Fibromyalgia With Recovery Factors

NCT04381780
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome
Interventions
Recovery Factors
Dietary Supplement
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kailua, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 31, 2026, 1:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513
View directory record Official record
Conditions
Limb-girdle Muscular Dystrophy
Interventions
SRP-9003, Glucocorticoid
Biological · Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
La Jolla, California • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Etanercept in Dermatomyositis

NCT00112385
View directory record Official record
Conditions
Dermatomyositis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 31, 2026, 1:18 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

NCT02597660
View directory record Official record
Conditions
Tendinopathy
Interventions
Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
Drug · Other · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
Richard Barohn, MD
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 31, 2026, 1:18 AM EDT
Not listed No phase listed Observational

Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping

NCT01772043
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
4 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Sacramento, California • Stanford, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 31, 2026, 1:18 AM EDT
Completed No phase listed Observational

Collaborative Assessment of ICU Recovery Needs

NCT03513289
View directory record Official record
Conditions
Post-Intensive Care Syndrome
Interventions
Patient, Carer, and Clinician Interviews
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 31, 2026, 1:18 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

NCT06130540
View directory record Official record
Conditions
Giant Cell Arteritis, Polymyalgia Rheumatica
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Boca Raton, Florida • Zephyrhills, Florida • Willowbrook, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 1:18 AM EDT